Arthur Sands, Nurix Therapeutics CEO

Nurix’s pro­tein de­grad­er over­comes re­sis­tance to BTK mu­ta­tions in small leukemia study

Pre­lim­i­nary re­sults from a small study of heav­i­ly treat­ed pa­tients with blood can­cer sug­gest that an ex­per­i­men­tal pro­tein de­grad­er, which re­moves prob­lem­at­ic pro­teins in­stead of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.